Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions (Q38729347)

From Wikidata

Jump to navigation Jump to search

scientific article published on 14 April 2017

Language	Label	Description	Also known as
English	Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions	scientific article published on 14 April 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

0 references

drug interaction

0 references

author name string

Xiaoyan Chu

1

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Grace Hoyee Chan

2

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Raymond Evers

3

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

language of work or name

0 references

publication date

14 April 2017

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Journal of Pharmaceutical Sciences

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

106

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

2357-2367

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Membrane transporters in drug development

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Comparing Various In Vitro Prediction Criteria to Assess the Potential of a New Molecular Entity to Inhibit Organic Anion Transporting Polypeptide 1B1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

The Complexities of Interpreting Reversible Elevated Serum Creatinine Levels in Drug Development: Does a Correlation with Inhibition of Renal Transporters Exist?

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

In vitro methods to support transporter evaluation in drug discovery and development

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

The role of organic anion transporting polypeptides in drug absorption, distribution, excretion and drug-drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Interspecies variability in expression of hepatobiliary transporters across human, dog, monkey, and rat as determined by quantitative proteomics

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Role of organic cation transporters in drug-drug interaction

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Enterohepatic bile salt transporters in normal physiology and liver disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Mammalian multidrug-resistance proteins (MRPs).

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

The heteromeric organic solute transporter, OSTα-OSTβ/SLC51: a transporter for steroid-derived molecules

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Recent advances in understanding hepatic drug transport

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Renal drug transporters and their significance in drug-drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Renal transporters in drug development

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Drug transport by Organic Anion Transporters (OATs).

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Drug-drug interactions involving membrane transporters in the human kidney

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Pharmacological and pathophysiological roles of carnitine/organic cation transporters (OCTNs: SLC22A4, SLC22A5 and Slc22a21).

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Proton-coupled oligopeptide transporter family SLC15: physiological, pharmacological and pathological implications

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Emerging transporters of clinical importance: an update from the International Transporter Consortium

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Evaluation of 4β-Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism-Based Pharmacometric Model

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Metabolomic and Genome-wide Association Studies Reveal Potential Endogenous Biomarkers for OATP1B1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Transporters and drug-drug interactions: important determinants of drug disposition and effects

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Xenobiotic transporters: ascribing function from gene knockout and mutation studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Species differences in drug transporters and implications for translating preclinical findings to humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Transportomics: screening for substrates of ABC transporters in body fluids using vesicular transport assays.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Targeted metabolomics identifies glucuronides of dietary phytoestrogens as a major class of MRP3 substrates in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Investigation of Endogenous Compounds Applicable to Drug-Drug Interaction Studies Involving the Renal Organic Anion Transporters, OAT1 and OAT3, in Humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Investigation of endogenous compounds for assessing the drug interactions in the urinary excretion involving multidrug and toxin extrusion proteins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Studies of bilirubin kinetics in normal adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Case study 5. Deconvoluting hyperbilirubinemia: differentiating between hepatotoxicity and reversible inhibition of UGT1A1, MRP2, or OATP1B1 in drug development

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

OATP1B1 POLYMORPHISM IS A MAJOR DETERMINANT OF SERUM BILIRUBIN LEVEL BUT NOT ASSOCIATED WITH RIFAMPICIN-MEDIATED BILIRUBIN ELEVATION

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Human UDP-glucuronosyltransferases: metabolism, expression, and disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Utility of bilirubins and bile acids as endogenous biomarkers for the inhibition of hepatic transporters

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Evaluation of rosuvastatin as an organic anion transporting polypeptide (OATP) probe substrate: in vitro transport and in vivo disposition in cynomolgus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Transporter pharmacogenetics and statin toxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Coproporphyrin I and III excretion in bile and urine

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Relevance of urinary coproporphyrin isomers in hereditary hyperbilirubinemias

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Dehydroepiandrosterone and dehydroepiandrosterone sulfate production in the human adrenal during development and aging

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Steroid hormones specifically modify the activity of organic anion transporting polypeptides.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Comparative Evaluation of Dehydroepiandrosterone Sulfate Potential to Predict Hepatic Organic Anion Transporting Polypeptide Transporter-Based Drug-Drug Interactions

2 references

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

based on heuristic

inferred from DOI database lookup

Dehydroepiandrosterone sulfate, a useful endogenous probe for evaluation of drug-drug interaction on hepatic organic anion transporting polypeptide (OATP) in cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

The role of 2-hydroxyacyl-CoA lyase, a thiamin pyrophosphate-dependent enzyme, in the peroxisomal metabolism of 3-methyl-branched fatty acids and 2-hydroxy straight-chain fatty acids

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Thiamine deficiency: an update of pathophysiologic mechanisms and future therapeutic considerations

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Involvement of organic cation transporters in the clearance and milk secretion of thiamine in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Thiamin uptake by the human-derived renal epithelial (HEK-293) cells: cellular and molecular mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

The predictive value of 131I-hippurate clearance in the prognosis of acute renal failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Renal disposition of a furan dicarboxylic acid and other uremic toxins in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Characterization of uremic toxin transport by organic anion transporters in the kidney

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Identification and Quantitative Assessment of Uremic Solutes as Inhibitors of Renal Organic Anion Transporters, OAT1 and OAT3.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Renal clearance of endogenous hippurate correlates with expression levels of renal organic anion transporters in uremic rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Evaluation of 6β-hydroxycortisol, 6β-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Effect of the fluoroquinolone antibacterial agent DX-619 on the apparent formation and renal clearances of 6β-hydroxycortisol, an endogenous probe for CYP3A4 inhibition, in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Quantitative urine amino acid analysis using liquid chromatography tandem mass spectrometry and aTRAQ reagents

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

The profile of bile acids and their sulfate metabolites in human urine and serum

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (OAT) 1 and OAT3 in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Cloning of the human thiamine transporter, a member of the folate transporter family

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Nonlinear kinetics of the thiamine cation in humans: saturation of nonrenal clearance and tubular reabsorption.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

N-methylnicotinamide is an endogenous probe for evaluation of drug-drug interactions involving multidrug and toxin extrusions (MATE1 and MATE2-K)

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Pharmacogenetics meets metabolomics: discovery of tryptophan as a new endogenous OCT2 substrate related to metformin disposition

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Transporters affecting biochemical test results: Creatinine-drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following oral microdosing

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2017.04.007

7 January 2021

Identifiers

10.1016/J.XPHS.2017.04.007

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38729347&oldid=1781291294"